RTP Mobile Logo
RTP TV: Part VIII — Chronic Myeloid Leukemia (CML)
Released August 2011

The final seminar of our eight-part online, integrated educational course explores topics relevant to the treatment of CML. Originally held on August 2, 2011, Part VIII features Drs Susan M O'Brien and Neil P Shah. (Webinar)

CE Disclosures and Faculty Information


    This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of hematologic cancers.


    CML accounts for 15 percent of adult leukemias. If left untreated, CML will progress from a chronic phase to a blast phase over approximately three to five years, leading to rapid disease progression and death. Once a largely incurable disease, the course of CML was dramatically altered in 2001 with the approval of a targeted therapy against the BCR-ABL kinase. Almost a decade later, persistent effort has been made to improve the therapeutic precision of BCR-ABL-targeted therapy while concurrently exploring a biologic understanding of de novo or acquired resistance to these targeted agents. Navigating the increasingly complex CML therapeutic algorithm has given rise to a distinct set of novel learning opportunities for oncologists and hematologists caring for patients with this disease. To bridge the gap between research and patient care, this CME activity will use a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians in the formulation of up-to-date and appropriate treatment strategies.


    • Apply current research findings to the care of patients with newly diagnosed CML.
    • Recognize evidence-based therapeutic options for patients with CML who experience disease progression on or intolerance to standard-dose imatinib.
    • Compare and contrast the benefits and risks of imatinib, nilotinib and dasatinib in the treatment of newly diagnosed CML.
    • Educate patients receiving BCR-ABL tyrosine kinase inhibitors about the incidence and management of side effects unique to individual agents and those generalizable to the therapeutic class.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Susan M O'Brien, MD
    Professor of Medicine
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No real or apparent conflicts of interest to disclose.

    Neil P Shah, MD, PhD
    Co-Leader, Hematologic Malignancies Program
    UCSF Helen Diller Comprehensive Cancer Center
    Assistant Professor of Medicine
    Division of Hematology/Oncology
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2011
    Expiration date: August 2012


Acknowledge and close

Watch Video
(WiFi is recommended for best performance):